CORONA — Corona Remedies Share Price
Last trade - 00:00- IN₹84.05bn
- IN₹84.06bn
- IN₹11.96bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.85 | ||
| Price to Tang. Book | 19.06 | ||
| Price to Free Cashflow | 85.03 | ||
| Price to Sales | 6.58 | ||
| EV to EBITDA | 31.05 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 34.05% | ||
| Return on Equity | 31.79% | ||
| Operating Margin | 18.25% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | n/a | 8,840.5 | 10,144.74 | 11,964.15 | n/a | n/a | 16.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +7.63 | +64.03 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.
Directors
- Last Annual
- March 31st, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- August 27th, 2004
- Public Since
- December 15th, 2025
- No. of Employees
- 4,573
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 61,160,088
- Address
- AHMEDABAD, 380059
- Web
- https://www.coronaremedies.com/
- Phone
- +91 7940233000
- Contact
- Chetna Dharajiya
- Auditors
- Deloitte Haskins & Sells LLP
Similar to CORONA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:06 UTC, shares in Corona Remedies are trading at IN₹1,374.30. This share price information is delayed by 15 minutes.
Shares in Corona Remedies last closed at IN₹1,374.30 and the price had moved by over the past 365 days. In terms of relative price strength the Corona Remedies share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreCorona Remedies does not currently pay a dividend.
Corona Remedies does not currently pay a dividend.
Corona Remedies does not currently pay a dividend.
To buy shares in Corona Remedies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹1,374.30, shares in Corona Remedies had a market capitalisation of IN₹84.05bn.
Here are the trading details for Corona Remedies:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: CORONA
Based on an overall assessment of its quality, value and momentum Corona Remedies is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Corona Remedies. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹1,374.30, shares in Corona Remedies were trading -2.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Corona Remedies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹1,374.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Corona Remedies' directors